PA is likely to act through multiple pathways, which could explain the inconsistency in previous findings, together with a limited power to analyze ER and PR status in breast tumors and PA [38,53,54,61], and the heterogeneity assessing PA which makes it difficult to compare results between studies. This evidence concerns the gene ESR1 and breast neoplasm.